Bayer has announced a new clinical trial of the latest entry in the race for radiopharmaceuticals to treat prostate cancer, joining 177Lu PSMA-617, 225Ac PSMA-617, and 131I MIP-1095. They are trying thorium-227 attached to a PSMA antibody. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: alpha-emitter, radiopharmaceutical, thorium-227, trial | Leave a comment »
The major, Switzerland-based, global pharmaceutical company Novartis has just agreed to acquire Endocyte — the developer of both Lu-177- PSMA-617 and Ac-225-PSMA-617, which are in clinical trials for the treatment of advanced forms of prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: Endocyte, Lu-177. Ac-225, Novartis, PSMA, radiopharmaceutical | Leave a comment »
We now have some details from clinical trials of the radiopharmaceutical actinium-225-PSMA-617 (Ac-225-PSMA-617) in very advanced prostate cancer patients. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: actinium-225, mCRPC, PSMA, radiopharmaceutical, trial | 9 Comments »
There are few radiopharmaceuticals in clinical trials in the US (although there are several in use in Germany), so when a new one is announced, we take notice. … READ MORE …
Filed under: Drugs in development | Tagged: Iodine-131-MIP-1095, radiopharmaceutical, Treatment | 9 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 